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Abstract
Background: We continue the previously described prospective cohort study of ritonovir-boosted lopinavir (LPV/r)
monotherapy for second-line therapy in HIV-infected patients with prior failure and extensive resistance to
nucleoside reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs), with
the objective being to determine the three-year treatment responses.
Findings: There were 40 patients with a mean ± SD age of 37 ± 8 years. Median (IQR) baseline CD4 was 123 (37-
245) cells/mm
3 and median (IQR) HIV-1 RNA was 55,800 (9,670-100,000) copies/mL. All patients received twice daily
LPV/r 400/100 mg and recycled lamivudine 150 mg. By intend-to-treat analysis at 144 weeks, 26 (65%) and 22
(56%) patients achieved HIV-1 RNA at < 400 and < 50 copies/mL, respectively. In as-treated analysis, the
corresponding rates were 26 of 28 (93%) and 22 of 28 (78%), respectively. Low-level viral rebound (HIV-1 RNA 50-
400 copies/mL) was found in 6 (15%), 6 (15%), and 4 (10%) patients at week 48, 96 and week 144, respectively.
Medians CD4 at week 48, 96, and 144 were 351, 481, and 584 cells/mm
3 and significantly changed from baseline
(all, P < 0.05). There were increments of mean triglycerides at 48 weeks and 144 weeks from baseline (P < 0.05). No
major protease resistance-associated mutations emerged after virologic failure.
Conclusion: LPV/r monotherapy with recycled lamivudine can maintain long-term virologic suppression in a
relatively small proportion of patients failing NNRTI-based regimen and having limit option for active NRTI. More
antiretroviral classes are needed be accessible in resource-limited countries.
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Findings
There are many concerns raised regarding boosted pro-
tease inhibitor monotherapy in HIV treatment include
this strategic treatment may not be as effective as other
combined antiretroviral therapies (ART), high rate of
low-level viremia and may lead to developing treatment
failure, and a higher level of adherence is required than
with the use of standard combined ART [1]. In addition,
there is an important concern about the ability of
monotherapy to penetrate viral reservoirs and prevent
viral replication in sanctuary sites, such as genital tract
and central nervous system. Studies evaluating ritonavir-
boosted protease inhibitor monotherapy that derived
from the western countries have been studied in three
patient settings including initial treatment, induction-
maintenance, and simplification monotherapy after
patients have been virologically suppressed - all are in
patients without treatment failure [2]. However, data
regarding durability of this strategic treatment is still
scanty, owing to supporting by only relatively short-
term data. On the other hand, HIV is often resistant to
most existing nucleoside reverse transcriptase inhibitors
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bitors (NNRTIs) among patients who have failed with
the first regimen in resource-constrained settings, sec-
ondary to the delayed detection of treatment failure.
Therefore, constructing the next antiretroviral regimens
that combined three fully active drugs for HIV-infected
patients with prior failure and extensive resistance to
NRTIs and NNRTIs in such setting is often impossible.
Therefore, we conducted a prospective cohort study of
ritonavir-boosted lopinavir monotherapy for the second-
line therapy in HIV-1 infected patients who failed anti-
retroviral regimens containing NRTIs and NNRTI as
previously described [3]. In the present analysis, we con-
tinued the prospective cohort study with the objectives
to determine the three-year virologic and immunologic
responses, and lipid derangements.
The present study was designed as a prospective
cohort study involving 40 HIV-1 infected patients who
were diagnosed virologic failure at the Bamrasnaradura
Infectious Diseases Institute, Ministry of Public Health,
Thailand. Virologic failure was defined as having viral
load > 1,000 copies/mL after 6 months of treatment or
a rebound of viral load to > 1,000 copies/mL in any
duration after undetectable viral load. Discontinuation
of lopinavir/ritonavir due to any reason was considered
to be a treatment failure, i.e. plasma HIV-1 RNA >
1,000 copies/mL. Inclusion criteria were as follows: (1)
HIV-1 infected patients > 18 years of age, (2) failed
NNRTI-based ART with M184V, thymidine analogue
mutations (TAMs) and NNRTI-associated mutations,
and (3) had plasma HIV-1 RNA > 1,000 copies/mL. The
patients were excluded if they had a history of exposure
to protease inhibitor or receipt a medication that has
drug-drug interactions with lopinavir or ritonavir. Rito-
navir-boosted lopinavir in soft gel formulation at 400/
100 mg and lamivudine at 150 mg were given twice
daily. Ritonavir-boosted lopinavir soft gel formulation
was changed to tablet formulation after 48 weeks of
treatment. CD4 cell counts (flow cytometry), plasma
HIV-1 RNA (Roche Amplicor, version 1.5), and lipid
profiles were measured every 24 weeks. Medication
adherence was assessed by pill count. All analyses were
performed using SPSS software, version 15.0 (SPSS Inc.,
Chicago, IL, USA). This study was reviewed and
approved by ethical committee for research in human
subjects of the Department of Diseases Control, Minis-
try of Public Health and by the institutional review
board.
As initial enrollment, there were 40 patients with a
mean ± SD age of 37 ± 8 years and 70% were males.
Median (IQR) baseline CD4 cell count was 123 (37-245)
cells/mm
3 and median (IQR) plasma HIV-1 RNA was
55,800 (9,670-100,000) copies/mL. Mean ± SD baseline
total cholesterol was 165 ± 42 mg/dL and mean ± SD
triglycerides was 172 ± 117 mg/dL. The frequencies of
each thymidine analogue associated mutation (TAMs)
were as follows: D67N, 17 (43%), T215FY, 16 (40%),
M41L, 8 (20%), K65R, 6 (15%), L210W, 6 (15%), and
K219Q, 2 (5%). M184V, Q151M and L74V were found
in 40 (100%), 7 (18%) and 2 (5%), respectively. The pre-
valence of patients with ≥1 major mutation conferring
drug resistance to NNRTIs was 100%.
Figure 1 displayed the proportion of patients who had
different stratum of plasma HIV-1 RNA at each follow-
up visit by intend-to-treat analysis. At 144 weeks, 26
(65%) and 22 (56%) patients had achieved plasma HIV-1
RNA at < 400 and < 50 copies/mL, respectively. In as-
treated analysis, the corresponding rates were 26 of 28
(93%) and 22 of 28 (78%), respectively. Low-level viral
rebound (HIV-1 RNA 50-400 copies/mL) was found in 6
(15%), 6 (15%), and 4 (10%) patients at week 48, 96 and
week 144, respectively. Medians CD4 cell count at weeks
48, 96, and 144 were 351, 481, and 584 cells/mm
3 and
significantly changed from baseline (all, P < 0.05). Com-
pared measures to baseline values, there were increments
o fm e a nt r i g l y c e r i d e sa t4 8w e e k sa n d1 4 4w e e k sf r o m
baseline (172 mg/dL vs. 338 mg/dL and 320 mg/dL, P <
0.05). LDL-cholesterol was not different (P > 0.05). No
major protease resistance-associated mutations emerged
after virologic failure. Three patients died over the study
period. The attributed causes of death were cryptococcal
meningitis (1 patient), sepsis (1), and hepatits B virus-
associated cirrhosis with fulminant hepatitis (1). Over the
study period, 36, 32, and 28 patients continued to follow-
up at weeks 48, 96, and 144 weeks.
A recent systematic review of lopinavir/ritonavir mono-
therapy demonstrated that overall response rate is not as
effective as either continuing combined ART or giving
ART at the beginning with relatively marginal significant
magnitude, i.e. 95% confidence interval for this determina-
tion was 1.02 to 2.13 [2]. Of note, this strategic treatment
appears most successful when patients are simplified from
suppressive ART regimens for a period of time rather than
starting monotherapy at the beginning [2]. Thus, this out-
come of lopinavir/ritonavir monotherapy among ART-
naïve patients may imply to our patients who experienced
NRTI and NNRTI treatment but were protease inhibitor-
naïve and had high plasma viral load at the beginning. Our
data indicate that the durability of ritonavir-boosted lopi-
navir monotherapy combined with recycled lamivudine
regarding virologic suppression of patients who were fail-
ing NNRTI-based regimens with M184V, TAMs and
NNRTI mutations is somewhat unfavorable. A recent pre-
liminary data of a randomized, controlled, trail demon-
strated that patients who failed NNRTI-based ART
regimens and who were protease inhibitor-naive, ritona-
vir-boosted lopinavir monotherapy and ritonavir-boosted
lopinavir combined with tenofovir/emtricitabine regimen
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RNA < 400 copies/mL, but not for < 50 copies/mL [4]. It
i sc o n s i s t e n tw i t ht h ep r e s e n ts t u d ys h o w i n gah i g hp r o -
portion of patients with persistent viremia throughout the
three-year follow-up period. One possible explanation is
the lack of viral suppression in some compartments, such
as genital secretion and cerebrospinal fluid [5]. Another
explanation is an alternative pathway of protease inhibitor
resistance facilitated by the absence of the NRTI drugs,
different HIV subtypes influence on polymorphisms, and a
non-adherence issue [6,7]. However, HIV resistant strains
may be present at levels below the limit of detection of the
test. One of our patients with unsuppressed viral load
throughout the study period had compliance of less than
80%. Nonetheless, emerging protease resistance-associated
mutation in patients who developed virologic failure with
is rare in the previous reports [8,9]. In terms of immunolo-
gic outcome, the present study reveals that ritonavir-
boosted lopinavir showed a great performance on the
immunological response after three years of treatment.
Another concern is that the efficacy in reservoirs is still
uncertain as aforementioned. Previous data showed that
most of the patients had undetectable HIV-1 RNA in
semen and vaginal compartment with ritonavir-boosted
lopinavir monotherapy [10]. Nonetheless, Gutmann and
colleagues showed that elevated viral load in cerebrosp-
inal fluid and abnormal neurological symptoms were
found in the patients who had virologic rebound after
simplified maintenance with ritonavir-boosted lopinavir
monotherapy [11]. Since the central nervous system
penetration-effectiveness score is lower for boosted pro-
tease inhibitor monotherapy than for standard combined
ART, it has been postulated that boosted protease inhibi-
tor monotherapy might have a higher risk for virological
failure in the central nervous system and it would contri-
bute to further neurocognitive impairment [12,13].
T h i ss t u d yp r o v i d e se v i d e n c et h a tl o n g - t e r mv i r o l o g i c
control is possible in the patients failing NNRTI-based
regimen and having limited options for active NRTI with
receiving ritonavir-boosted lopinavir monotherapy and
recycled lamivudine. However, this success is in a rela-
tively small proportion of patients. Ritonavir-boosted lopi-
navir monotherapy should be prescribed with caution as a
second-line option, especially in settings where close viral
load monitoring is not available. As a consequence, more
antiretroviral classes to assure the potency of the regimen
are needed to be accessible in many resource-constrained
settings. A further larger study is required to assess the
risk and benefit of this proposed strategic treatment.
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